CFS 1500 C for fast capsule filling

Published: 10-Feb-2010 Featured companies: Lonza
Manufacturing Packaging Drug Delivery Pharmaceutical

An automated CFS 1500 C (containment) capsule filling and sealing system is now available from Capsugel, of Cambridge, UK, to provide rapid and safe filling and sealing of capsules containing lipid-based formulations or potent compounds for use in early phase clinical trials.

An automated CFS 1500 C (containment) capsule filling and sealing system is now available from Capsugel, of Cambridge, UK, to provide rapid and safe filling and sealing of capsules containing lipid-based formulations or potent compounds for use in early phase clinical trials.

The CFS 1500 C, which uses Capsugel's Licaps drug delivery technology, offers many of the timesaving benefits of the established CFS 1200. Additionally, it has accessible moving parts, which can be removed for manual or auto washer cleaning.

The CFS 1500 C has a throughput of 1,500 filled and sealed capsules per hour and is scalable to commercial manufacturing using the LEMS 70 liquid encapsulation micro-spray sealing system, which is capable of sealing up to 70,000 capsules per hour.

With the LEMS 70 and Licaps capsules, the CFS 1500 C can fill and seal capsules with a robust, impervious seal.

New software provides the CFS 1500 C with greater functionality and a weigh cell feature measures the weight of each filled capsule to ensure compliance with 21 CFR part 11.




Featured companies

As a dedicated CDMO serving the healthcare industry, we bring life-enhancing and life-saving treatments to market for our customers and their patients. We are a pioneer and...
See more

You may also like

Manufacturing

Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing

Read more
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics

Trending Articles

  1. MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
  2. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  3. embecta completes £100m acquisition of UK-based Owen Mumford to bolster drug delivery portfolio US diabetes care company embecta has finalised its acquisition of Owen Mumford, gaining access to the Aidaptus next-generation auto-injector platform as it accelerates its transition into a broad-based medical supplies company
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Wearable pumps and subcutaneous delivery: a new frontier in heart failure management Two recent developments are reshaping how drug delivery technology can move treatment out of the clinic and into patients’ everyday lives — with implications for both formulation science and device manufacturing
  5. How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies

Relevant companies

See more

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing

New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing

Lonza delivers strong performance in Q1 2026 in line with expectations and confirms full-year Outlook 2026

Basel, Switzerland, 8 May 2026 – In its qualitative Q1 2026 business update, Lonza1 reported a strong performance across its CDMO business in line with the expected trajectory for Full-Year 2026. As expected, due to a lower prior year base, campaign timing and product releases, and planned site shutdowns, CER sales growth and CORE EBITDA margin will be notably stronger in the first half of 2026 than in the second half
Manufacturing

Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target

BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Manufacturing

ImmuneOncia Therapeutics and Lonza collaborate to manufacture Danburstotug

Lonza to support development and manufacturing of ImmuneOncia’s Danburstotug with a complete and integrated end-to-end drug substance and drug product solution
Manufacturing

Lonza and Genetix extend commercial manufacturing agreement for ZYNTEGLO™

Expanded collaboration will support growing demand for FDA-approved gene therapy for beta-thalassemia
Manufacturing

Lonza completes transformation to pure-play CDMO with agreement to divest Capsules & Health Ingredients

Sale of CHI business to Lone Star funds marks final step in Lonza’s strategic shift to a focused CDMO model
Subscribe now